Navigation Links
Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement

IRVINE, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has filed a motion to stay, or discontinue all proceedings in, the patent infringement lawsuit brought against it in October 2009 by Cook, Inc. The motion was filed in the United States District Court in Indianapolis, Indiana.

Endologix has requested that the stay remain in effect while the United States Patent and Trademark Office (USPTO) conducts proceedings to re-examine the two patents asserted by Cook in the lawsuit and determine whether it should have granted Cook the patents. Endologix has already filed papers requesting that the USPTO re-examine the two Cook patents, based on patents that pre-date Cook's patents and were not previously considered by the USPTO in its decision to grant the patents to Cook.

John McDermott, Endologix President and Chief Executive Officer, said, "In addition to contesting the validity of Cook's patents, we also intend to challenge the lawsuit on other grounds, including non-infringement of the Cook patents by our products. We continue to believe we have support for numerous promising defenses against this infringement case."

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements, specifically related to the claims of alleged infringement. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

Endologix, Inc.                      The Ruth Group
John McDermott, CEO                  Nick Laudico (646) 536-7030
(949) 595-7200                       Zack Kubow (646) 536-7020

SOURCE Endologix, Inc.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. Endologix Responds to Alleged Patent Infringement
3. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
4. Endologix Reports 47% Third Quarter 2009 Revenue Growth
5. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
6. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
7. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
8. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
9. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
10. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
11. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
Post Your Comments:
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
(Date:6/23/2016)... 2016 The Biotechnology industry might ... present great opportunities to investors. assesses the recent ... (NYSE: XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):